Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion - 14/03/19
, Bang-De Xiang a, b, c, ⁎ 
Abstract |
Background |
Microvascular invasion (MVI) has recently been reported to be an independent prognostic factor in patients with hepatocellular carcinoma (HCC). This study compared the outcomes of adjuvant transarterial chemoembolization (A-TACE) after hepatic resection (HR) in patients with HCC involving MVI.
Methods |
This prospective study involved 200 consecutive patients with MVI-HCC who underwent HR alone (n = 109) or HR with A-TACE (n = 91).The Kaplan-Meier method was used to compare disease-free survival (DFS) and overall survival (OS).
Results |
The two groups showed similar DFS at 1, 2, and 3 years (P = 0.077). The A-TACE group showed significantly higher OS than the HR-only group (P = 0.030). Subgroup analysis showed that A-TACE was associated with significantly higher DFS and OS among patients with a tumor diameter >5 cm or with multinodular tumors.
Conclusions |
A-TACE may improve postoperative outcomes for MVI-HCC patients, especially those with tumor diameter >5 cm or multinodular tumors.
Il testo completo di questo articolo è disponibile in PDF.Highlights |
• | Microvascular invasion (MVI) has been reported to be an independent prognostic factor in HCC patients. |
• | Our study suggest that adjuvant transarterial chemoembolization (A-TACE) may improve postoperative overall survival (OS), but without improving disease-free survival (DFS). |
• | Further, our data fond that the survival benefit of A-TACE was particularly evident among MVI-HCC patients with recurrence risk factors, such as tumor diameter >5 cm and multinodular disease. |
Keywords : Adjuvant, Hepatic resection, Hepatocellular carcinoma, Microvascular invasion, Transarterial chemoembolization
Mappa
Vol 217 - N° 4
P. 739-744 - aprile 2019 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
